| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.019 | 0.8 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |